NCT06662825View on ClinicalTrials.gov

Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers

CompletedOBSERVATIONAL
Enrollment

376

Participants

Timeline

Start Date

December 13, 2022

Primary Completion Date

November 1, 2023

Study Completion Date

November 1, 2023

Conditions
Sickle Cell Disease
Trial Locations (1)

07936

Novartis Pharmaceuticals, East Hanover

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT06662825 - Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers | Biotech Hunter | Biotech Hunter